Past success is an excellent of predictor of future success in commercialization. Our achievements demonstrate that BLG has the skills, knowledge and experience to help you.
Read highlights below for a selection of featured license agreements and licensing relationships with established industry partners, investor groups, and startup companies, as well as collaboration with our peer academic institutions to commercialize jointly-developed inventions.
Developments with Longstanding Licensing Relationships
- Takeda Pharmaceuticals
A Decade of Academia-Industry Joint Efforts in Developing a Human Norovirus Vaccine Candidate.
- Opexa Therapeutics, Inc.
Opexa Therapeutics Reaches Clinical Development Milestone Event in Development of a Personalized Therapy for Secondary Progressive Multiple Sclerosis.
- TyRx, Inc.
TyRx, Inc., Expands Market and Introduces Bioresorbable AIGISRx R Antibacterial Envelope.
Exclusive License Agreements
- Celgene Corporation
Celgene, bluebird bio, and the Center for Cell and Gene Therapy Combine Strengths and Resources to Develop T-cell Based Therapies for Cancer
- Vax-Immune, LLC
Vax-Immune Acquires Exclusive Worldwide Rights to Baylor College of Medicine’s Ureaplasma Technology.
- Shenzhen Tiande Investment Co., LTD.
Shenzhen Tiande Investment Co., LTD., Licenses Esophageal Cancer Biomarkers.
- Acer Therapeutics, Inc.
Acer Therapeutics Develops the First Pharmaceutical Therapy for Maple Syrup Urine Disease (MSUD)
- StemMed, Ltd.
StemMed, Ltd., Licenses STAT3 Inhibitors - Local Company Developing Novel Compounds Against a Key Cancer Target
- American Type Culture Collection (ATCC)
ATCC Master Agreement - BCM Poised to Benefit from Commercial Use of Deposited Materials.